Lupus Anticoagulant Testing Market Is Set to Experience Revolutionary Growth by 2029

Posted byEditor AN Leave a comment on Lupus Anticoagulant Testing Market Is Set to Experience Revolutionary Growth by 2029

Lupus Anticoagulant Testing Market Overview

Lupus anticoagulants (LA) are antibodies directed against phospholipid-binding proteins that prolong phospholipid-dependent coagulation assays. Lupus anticoagulant testing is a special blood test to find out if certain antibodies or proteins that cause blood-clotting disorders are present. Persistent lupus anticoagulant testing positivity is a risk factor for the occurrence and recurrence of venous/arterial thromboembolism and/or pregnancy morbidity and qualifies the patient for lupus anticoagulant testing. The antibodies to be tested are present in about 2-4% of the general population and may develop in people with no known risk factors. Initial lupus anticoagulant testing typically involves one or more tests that depend on phospholipid-containing reagents, usually partial thromboplastin time (PTT), the LA-sensitive PTT (known as PTT-LA) or dilute Russell viper venom test (DRVVT). The undiagnosed patients are at a constant risk of developing antiphospholipid syndrome, a disease that provokes blood clots in arteries and veins.

Lupus Anticoagulant Testing: Market Drivers and Restrains

Recurrent thrombosis in patients with blood disorders is expected to rise the demand for lupus anticoagulant testing. According to NIH, it is estimated that 20 percent of individuals younger than age 50 who have a stroke have antiphospholipid syndrome which would rise the size of lupus anticoagulant testing market with rising awareness. Blood disorders like anemia and bleeding disorders such as hemophilia, blood clots, and blood cancers such as leukemia, lymphoma, and myeloma are on rise. Von Willebrand disease (VWD) is a bleeding disorder in which blood doesn’t clot properly. Between 2012 and 2016, more than 14,600 men, women, and children were seen at hemophilia treatment centers for treatment of VWD in the U.S which is expected to increase the demand for lupus anticoagulant testing. The number of traumatic injuries and wounds are on a rise which could be a reason for rising number of lupus anticoagulant testing done annually to confirm blood disorders.

Lupus Anticoagulant Testing Market: Overview

The lupus anticoagulant testing market is structured differently depending on the regions. North America and Europe has a number of diagnostic laboratories to avail for lupus anticoagulant testing. On the other hand, the existence of the condition is not known. The dependence on hospitals for primary blood related disorders in remote rural areas in Asia-Pacific and African countries is not observed in the developed lupus anticoagulant testing markets. Blood clots observed in patients with blood related cancers such as leukemia, lymphoma, and myeloma are expected to fuel the demand for lupus anticoagulant testing.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10746

Lupus Anticoagulant Testing Market: Key Players

Some of the key players present in global lupus anticoagulant testing market include Becton Dickinson, Abbott, AstraZeneca plc, F. Hoffmann-La Roche Ltd, Vertex Pharmaceuticals Inc, Novartis AG, Boehringer Ingelheim GmbH, Mylan N.V. and leading diagnostic laboratories within respective countries. With active mergers and acquisitions, the lupus anticoagulant testing market is changing the structure and presence of various small players active in the lupus anticoagulant testing market.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For any queries linked with the report, ask an analyst https://www.futuremarketinsights.com/ask-question/rep-gb-10746

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Leave a comment

Your email address will not be published. Required fields are marked *